Gynecologic Cancers

FDA Approves Dostarlimab for dMMR Advanced Endometrial Cancer

April 22, 2021

The FDA approved dostarlimab (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that progressed on or after platinum-containing chemotherapy and whose cancer is DNA mismatch repair deficient (dMMR), as determined by an FDA-approved test.

HRD Testing Expands, But Still Lacks Standardization in Ovarian Cancer

April 09, 2021

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.

Maintenance Olaparib Still Beneficial at 5-Year Mark

March 23, 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Immunotherapy in Ovarian Cancer: Don't Give Up, Yet

March 16, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

Study Explores Actionable Pathologic Variants in Caribbean Women With Breast or Ovarian Cancer

March 11, 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

OVAL Trial Gets the OK to Continue for Patients With Ovarian Cancer

February 27, 2021

An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

Secondline Maintenance PARP Inhibition in Ovarian Cancer: Pros and Cons

January 02, 2021

“Second-line maintenance therapy is going to be incredibly important for patients because we know that once a patient with ovarian cancer recurs, their disease is incurable,” said Puechl. “Second-line maintenance therapy should be considered for these patients because it can [provide] meaningful time that is largely free of [chemotherapy-related] toxicities.”

Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go

November 07, 2020

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

PARP Inhibitor Resistance in Ovarian Cancer: We Need More Trials

November 03, 2020

While PARP inhibitors have played a large part in improving progression-free survival (PFS) in patients with ovarian cancer, long-term use of these agents often leads to resistance that are often quite challenging to overcome, according to Gottfried E. Konecny, MD.